- Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
- Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Friday, Crinetics Pharmaceuticals Inc (CRNX:NSQ) closed at 47.20, -4.80% below its 52-week high of 49.58, set on Apr 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.52 |
---|---|
High | 48.37 |
Low | 47.13 |
Bid | 42.00 |
Offer | 52.40 |
Previous close | 47.20 |
Average volume | 635.67k |
---|---|
Shares outstanding | 78.74m |
Free float | 75.75m |
P/E (TTM) | -- |
Market cap | 3.72bn USD |
EPS (TTM) | -3.70 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼